AnHeart Therapeutics Expands U.S. Leadership With Development and Commercial Leads
AnHeart Therapeutics (“AnHeart”), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, today announced the appointments of Guilin Huang as Senior Vice President, Development and Amy Muse as Vice President, U.S. Commercial.
- AnHeart Therapeutics (“AnHeart”), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, today announced the appointments of Guilin Huang as Senior Vice President, Development and Amy Muse as Vice President, U.S. Commercial.
- Amy joins AnHeart with more than 20 years of commercial experience in the pharmaceutical and biotech industry.
- Amy will lead commercial strategy for AnHeart’s investigational precision therapies in the United States, focusing initially on preparing AnHeart for the commercial launch of taletrectinib.
- Prior to Takeda, Amy held several commercial roles, including marketing and sales positions, at Shire, Forest Laboratories, and Merck and Co.